AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04333602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinary culture and treatment if asymptomatic bacteriuria is detected
Description: Urinary culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. Based in the assigned group If we detect asymptomatic bacteriuria specific treatment will be instituted or No treatment.
Study NCT03009643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
Study NCT02729246 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Gastric Bypass
Study NCT00708266 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Openflow microperfusion catheter
Description: Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
Study NCT00708266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Openflow microperfusion catheter
Description: Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
Study NCT00708266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Description: Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits.
Study NCT00708266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Solution
Description: 0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits.
Study NCT02725372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide 75 mcg/kg IBW/hr
Description: Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
Study NCT02725372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
Study NCT01240590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crolibulin
Description: Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
Study NCT01240590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crolibulin
Description: Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
Study NCT01240590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
Study NCT01240590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
Study NCT02467985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIGARO
Description: flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
Study NCT00860457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
Study NCT00860457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
Study NCT00860457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
Study NCT01583959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid tablets 5 mg
Study NCT01583959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
Study NCT00651326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Study NCT03000478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Study NCT03000478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Study NCT00273689 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: montelukast vs pretreatment with albuterol
Description: montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
Study NCT03009643 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: lung protective mechanical ventilation
Description: Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
Study NCT03009643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung protective mechanical ventilation
Description: Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
Study NCT03009643 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hemodynamic monitoring
Description: Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
Study NCT00273689 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: montelukast
Description: Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
Study NCT04357548 — intervention group
Intervention type: DEVICE
Intervention: FEEDBACK
Description: Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
Study NCT00553176 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
Study NCT00611260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vipassana Meditation practice and instruction
Description: 2-3 instructed meditation sessions per week in addition to standard medical care.
Study NCT00611260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care
Description: Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
Study NCT06632574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel cationic liposomes
Description: Paclitaxel cationic liposomes is a modified new drug. In this study, administration is performed through arterial catheter infusion.
Study NCT04980989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile software for follow-up of early breast cancer
Description: The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
Study NCT04980989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile software for follow-up of early breast cancer
Description: The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
Study NCT02535793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood test (four dry tubes 7ml) and prick tests
Study NCT00143390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
Study NCT00143390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
Study NCT02889523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tablets 200 mg, to be administrated per os
Study NCT02889523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m²/dose, D1
Study NCT02889523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m²/dose, D1
Study NCT02889523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m²/dose (max 2 mg), D1
Study NCT02889523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m²/dose, D1
Study NCT03009643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodynamic monitoring
Description: Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
Study NCT00758121 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy Defibrillator
Description: CRT-D observational study
Study NCT03303898 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: sampling of 7 blood tubes
Study NCT00886119 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lens
Description: Silicone hydrogel, soft, multifocal contact lens for daily wear use
Study NCT00886119 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Omafilcon A multifocal contact lens
Description: Hydrogel, soft, multifocal contact lens for daily wear use
Study NCT03854890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
Study NCT04900948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Description: Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
Study NCT04900948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cream 0.1% methylprednisolone aceponate
Description: Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
Study NCT01503996 — intervention group
Intervention type: BEHAVIORAL
Intervention: alter drinking habits
Description: if dehydration is apparent, more fluid intake is recommended
Study NCT02889523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40 mg/m2 in the morning D1 to D5
Study NCT02468856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
Study NCT02468856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for armodafinil)
Description: Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
Study NCT01739699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT01739699 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT04625491 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT02827695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMASK
Description: Medication adherence and BP monitoring
Study NCT02827695 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EnhancedSC
Description: Standard care without med reminder functions with healthy lifestyle texts
Study NCT04236882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Attend focus group
Study NCT03002623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-907
Description: 60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
Study NCT04236882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Receive educational material on healthy homes
Study NCT04236882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive web-based sleep intervention
Study NCT04236882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive web-based health coaching sessions
Study NCT04236882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Receive web-based counseling sessions
Study NCT04236882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview
Study NCT04236882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Complete interview
Study NCT04236882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02864251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT02864251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT04236882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02864251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT03296254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting Mindfulness Exercises.
Description: 5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
Study NCT03296254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Mindfulness Exercises
Description: 5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
Study NCT01165255 — intervention group
Intervention type: DRUG
Intervention: 3. Exposure to other antidepressants during the first trimester comparison cohort
Description: Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy.
Study NCT01165255 — intervention group
Intervention type: DRUG
Intervention: 2. Exposure to bupropion outside the first trimester comparison cohort
Description: Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester.
Study NCT01165255 — intervention group
Intervention type: DRUG
Intervention: 1. Exposure to bupropion during the first trimester
Description: Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy.
Study NCT02404376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Intravenous administration of Exenatide
Study NCT03930550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation by endoscopy with flexible bronchoscope
Description: A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
Study NCT03930550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation by endoscopy with flexible bronchoscope
Description: A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
Study NCT02418988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE plus rAd-p53 artery injection
Description: Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
Study NCT04011670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg caffeine tablet
Description: * Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition
Study NCT04011670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-active tablet
Description: * Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition
Study NCT02404376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: Remote ischemic conditioning with a cuff in the arm
Study NCT00609999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib and Dasatinib
Description: You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.
Study NCT04036110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg
Description: 500 mg tablet taken orally with one meal daily
Study NCT04036110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg
Description: 1000 mg tablet taken orally with one meal daily
Study NCT04036110 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet taken orally with one meal daily